DE19975040I2 - Medikamente enthaltend Salmeterol und Fluticason - Google Patents

Medikamente enthaltend Salmeterol und Fluticason

Info

Publication number
DE19975040I2
DE19975040I2 DE1990605951 DE69005951C DE19975040I2 DE 19975040 I2 DE19975040 I2 DE 19975040I2 DE 1990605951 DE1990605951 DE 1990605951 DE 69005951 C DE69005951 C DE 69005951C DE 19975040 I2 DE19975040 I2 DE 19975040I2
Authority
DE
Germany
Prior art keywords
fluticasone
salmeterol
medications containing
containing salmeterol
medications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1990605951
Other languages
German (de)
English (en)
Other versions
DE69005951T2 (de
DE69005951D1 (de
Inventor
James Barry Douglas Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19975040(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE19975040I2 publication Critical patent/DE19975040I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE1990605951 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason Active DE19975040I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
DE19975040I2 true DE19975040I2 (de) 2006-07-13

Family

ID=27264677

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1990605951 Active DE19975040I2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason
DE69005951T Expired - Lifetime DE69005951T2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69005951T Expired - Lifetime DE69005951T2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason.

Country Status (20)

Country Link
EP (1) EP0416951B1 (OSRAM)
JP (1) JP3042867B2 (OSRAM)
AT (1) ATE99941T1 (OSRAM)
BE (1) BE1003053A3 (OSRAM)
CA (1) CA2024916C (OSRAM)
CH (1) CH680983C9 (OSRAM)
DE (2) DE19975040I2 (OSRAM)
DK (1) DK0416951T3 (OSRAM)
ES (1) ES2062392T3 (OSRAM)
FR (1) FR2651677B1 (OSRAM)
HK (1) HK18695A (OSRAM)
HU (1) HU211272A9 (OSRAM)
IE (1) IE65535B1 (OSRAM)
IL (1) IL95590A (OSRAM)
IT (1) IT1241996B (OSRAM)
LU (1) LU90392I2 (OSRAM)
NL (1) NL990012I2 (OSRAM)
NZ (1) NZ235221A (OSRAM)
PH (1) PH27594A (OSRAM)
SG (1) SG166294G (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
JP3342484B2 (ja) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB2354007B (en) 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU7576001A (en) * 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE60321311D1 (de) † 2002-02-04 2008-07-10 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
WO2003074469A1 (de) * 2002-03-04 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue zimtsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
EP1572217B1 (en) 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
DK1658063T3 (da) 2003-08-06 2014-05-12 Galephar M F Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
AP2006003734A0 (en) * 2004-03-12 2006-10-31 Cipla Ltd Inhalation formulation
PL1616592T3 (pl) 2004-07-16 2011-03-31 Astrazeneca Ab Inhalator do podawania sproszkowanych środków farmaceutycznych i proszkowa kaseta do użycia z tym inhalatorem
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2435025B1 (en) 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
US20160158149A1 (en) * 2013-04-29 2016-06-09 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
FR2651677A1 (fr) 1991-03-15
DE69005951T2 (de) 1994-05-26
EP0416951A1 (en) 1991-03-13
SG166294G (en) 1995-06-16
IL95590A (en) 1996-06-18
BE1003053A3 (fr) 1991-11-05
DE69005951D1 (de) 1994-02-24
HU211272A9 (en) 1995-11-28
CH680983C1 (OSRAM) 2008-06-25
HK18695A (en) 1995-02-17
IT9048260A0 (it) 1990-09-07
NL990012I1 (nl) 1999-07-01
IE65535B1 (en) 1995-11-01
ES2062392T3 (es) 1994-12-16
LU90392I2 (fr) 1999-06-28
IE903256A1 (en) 1991-03-13
CH680983C9 (OSRAM) 2008-08-15
EP0416951B1 (en) 1994-01-12
PH27594A (en) 1993-08-31
CH680983A5 (OSRAM) 1992-12-31
NL990012I2 (nl) 1999-09-01
FR2651677B1 (fr) 1993-08-06
CA2024916A1 (en) 1991-03-09
ATE99941T1 (de) 1994-01-15
NZ235221A (en) 1992-11-25
IL95590A0 (en) 1991-09-16
IT9048260A1 (it) 1992-03-07
DK0416951T3 (da) 1994-02-14
CA2024916C (en) 2002-07-09
JP3042867B2 (ja) 2000-05-22
IT1241996B (it) 1994-02-02
JPH03167120A (ja) 1991-07-19

Similar Documents

Publication Publication Date Title
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
DE69002718D1 (de) Medikamente.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
CA2123909A1 (en) New combination of formoterol and budesonide
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69918961D1 (de) Verbesserte inhalationspräparate
MY111155A (en) Medicaments
JPS6438027A (en) Remedy for cancer
RU93003456A (ru) Лекарственный препарат
RU93003454A (ru) Лекарственный препарат